PHASE III MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL COMPARING EFFICACY+SAFETY OF POLATUZUMAB VEDOTIN IN COMBO WITH R-CHP VS R-CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Brief description of study
If you have been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL) that has previously been untreated, you may qualify for this study. The main goal of this Phase III study of this study is to compare the effects of polatuzumab vedotin in combination with four other drugs, rituximab (R) (also known as Rituxan® and MabThera®), cyclophosphamide (C), doxorubicin (H), and prednisone (P) (when given together, referred to as R-CHP); compared with vincristine (O) in combination with R-CHP (referred to as R-CHOP) on you and your lymphoma.
Clinical Study Identifier: s17-00794
ClinicalTrials.gov Identifier: NCTs17-00794
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
